Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Short Interest Update

Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) saw a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 7,300 shares, a decline of 33.6% from the February 13th total of 11,000 shares. Approximately 0.2% of the company’s shares are sold short. Based on an average daily volume of 14,300 shares, the days-to-cover ratio is currently 0.5 days.

Hedge Funds Weigh In On Lakeshore Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of the company. Barclays PLC acquired a new position in shares of Lakeshore Biopharma in the 3rd quarter worth approximately $169,000. Orbimed Advisors LLC acquired a new stake in Lakeshore Biopharma during the 4th quarter worth approximately $486,000. FMR LLC acquired a new stake in Lakeshore Biopharma during the 3rd quarter worth approximately $803,000. Finally, Hhlr Advisors LTD. acquired a new stake in Lakeshore Biopharma during the 3rd quarter worth approximately $513,000. 52.64% of the stock is currently owned by institutional investors and hedge funds.

Lakeshore Biopharma Price Performance

NASDAQ:LSB traded up $0.05 on Monday, hitting $2.05. The stock had a trading volume of 2,147 shares, compared to its average volume of 19,912. The company has a debt-to-equity ratio of 0.13, a quick ratio of 0.90 and a current ratio of 1.17. The company has a fifty day moving average price of $2.45 and a two-hundred day moving average price of $3.38. Lakeshore Biopharma has a 1-year low of $1.81 and a 1-year high of $11.20.

About Lakeshore Biopharma

LakeShore Biopharma Co, Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People’s Republic of China and Other Countries or Regions.